NeuroMetrix, Inc. (NURO)

NASDAQ: NURO · IEX Real-Time Price · USD
3.700
-0.140 (-3.65%)
At close: Jul 12, 2024, 4:00 PM
3.680
-0.020 (-0.54%)
After-hours: Jul 12, 2024, 7:06 PM EDT
-3.65%
Market Cap 7.44M
Revenue (ttm) 5.27M
Net Income (ttm) -7.98M
Shares Out 2.01M
EPS (ttm) -6.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,959
Open 3.766
Previous Close 3.840
Day's Range 3.700 - 3.824
52-Week Range 2.700 - 7.920
Beta 2.31
Analysts n/a
Price Target n/a
Earnings Date Jul 25, 2024

About NURO

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disp... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1996
Employees 26
Stock Exchange NASDAQ
Ticker Symbol NURO
Full Company Profile

Financial Performance

In 2023, NeuroMetrix's revenue was $5.90 million, a decrease of -28.52% compared to the previous year's $8.26 million. Losses were -$6.53 million, 47.8% more than in 2022.

Financial Statements

News

NeuroMetrix Reports Q1 2024 Business Highlights

WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.

2 months ago - GlobeNewsWire

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enh...

3 months ago - GlobeNewsWire

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alo...

4 months ago - GlobeNewsWire

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec 2022.

4 months ago - GlobeNewsWire

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

NURO stock price has declined 99% since its IPO Gozani has received compensation of over $10 million since the IPO Gozani was charged by the FTC for various wrongdoings at NURO Gozani apparently perso...

4 months ago - Accesswire

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

- Stock trades significantly below its net cash per share - Questions the Board's ability and/or desire to create shareholder value - Notes tremendous destruction of shareholder value under company's ...

4 months ago - Accesswire

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.

5 months ago - GlobeNewsWire

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.

5 months ago - GlobeNewsWire

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes...

5 months ago - GlobeNewsWire

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

NeuroMetrix announced today that the Company's Chairman and CEO, Dr. Shai N. Gozani will present at the Emerging Growth Conference on January 10, 2024.

6 months ago - GlobeNewsWire

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

WOBURN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patient...

7 months ago - GlobeNewsWire

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain.

7 months ago - GlobeNewsWire

NeuroMetrix Announces One-for-Eight Reverse Stock Split

WOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on Novembe...

8 months ago - GlobeNewsWire

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

WOBURN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023.

9 months ago - GlobeNewsWire

NeuroMetrix Reports Q3 2023 Business Highlights

WOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023.

9 months ago - GlobeNewsWire

NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call

NeuroMetrix, Inc. announced today that it plans to issue its Q3 2023 business and financial highlights on October 26, 2023 at 8:00 a.m., Eastern Time.

9 months ago - GlobeNewsWire

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

WOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA).

10 months ago - GlobeNewsWire

NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023

WOBURN, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on October 4, 2023.

10 months ago - GlobeNewsWire

NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023

WOBURN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on September 6, 2023. This live, interactive, ...

11 months ago - GlobeNewsWire

NeuroMetrix Reports Q2 2023 Business Highlights

WOBURN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023. The Compan...

1 year ago - GlobeNewsWire

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market ...

1 year ago - GlobeNewsWire

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

WOBURN, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption of Quell® Fibromyalgia, which is the first and ...

1 year ago - GlobeNewsWire

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

WOBURN, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people wi...

1 year ago - GlobeNewsWire

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

WOBURN, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK. The scientific p...

1 year ago - GlobeNewsWire

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial o...

1 year ago - GlobeNewsWire